DYRK3 contributes to differentiation and hypoxic control in neuroblastoma

Biochem Biophys Res Commun. 2021 Aug 27:567:215-221. doi: 10.1016/j.bbrc.2021.06.053. Epub 2021 Jun 22.

Abstract

Neuroblastoma (NB), a pediatric cancer of the peripheral sympathetic nervous system, represents the most frequent solid malignancy in infants. Treatment of high-risk patients is still challenging and, depending on the genetic make-up and involved risk factors, the 5-year survival rate can drop to only 30%. Here, we found that the expression of the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 3 (DYRK3) is increased in NB and is associated with decreased survival in NB patients. We further identified DYRK3 as a cytoplasmic kinase in NB cells and found that its levels are increased by hypoxic conditions. Further mechanistic studies revealed that DYRK3 acts as a negative regulator of HIF-driven transcriptional responses, suggesting that it functions in a negative feedback loop controlling the hypoxic response. Moreover, DYRK3 negatively impacted on NB cell differentiation, proposing an oncogenic role of this kinase in the etiology of NB. In summary, we describe novel functions of the DYRK3 kinase in NB, which will help to further improve the understanding of this disease eventually leading to the design of improved therapeutic concepts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Female
  • Humans
  • Mice
  • Neuroblastoma / metabolism*
  • Neuroblastoma / pathology
  • Protein Serine-Threonine Kinases / analysis
  • Protein Serine-Threonine Kinases / metabolism*
  • Protein-Tyrosine Kinases / analysis
  • Protein-Tyrosine Kinases / metabolism*
  • Tumor Hypoxia

Substances

  • DYRK3 protein, mouse
  • DYRK3 protein, human
  • Protein-Tyrosine Kinases
  • Protein Serine-Threonine Kinases